Keminger K, Kokoschka R, Schmalzer E
Wien Klin Wochenschr. 1983 Mar 18;95(6):214-9.
This paper attempts to review current opinions on medullary thyroid carcinoma. Histologically described for the first time in 1951 belongs to the endocrine-secreting group of tumours (APUD). It can be sporadic as well as hereditary. The histological classification nowadays is increasingly performed immunohistologically via calcitonin. Clinically the tumour ranges from the very small, but hormonally highly active form, to the aggressive, mostly undifferentiated form. According to this the therapy must be radical. Our study group recommends thyroidectomy and functional neck dissection, followed by radio-chemotherapy. A close interdisciplinary follow up of the patients is necessary. Our surgical department treated 1048 thyroid malignancies between 1949 and 1982. 26 patients (2.4%) were diagnosed to have medullary thyroid carcinoma. Follow up time was between 1 month and 17 years. The recurrence--free interval was 4.5 years. The 5 and 10 year survival rate was 52% and 26%, respectively.
本文旨在综述当前关于甲状腺髓样癌的观点。1951年首次在组织学上被描述，它属于内分泌分泌性肿瘤组（APUD）。它可以是散发性的，也可以是遗传性的。如今，组织学分类越来越多地通过降钙素进行免疫组织化学分析。临床上，肿瘤范围从非常小但激素活性很高的形式到侵袭性的、大多未分化的形式。据此，治疗必须彻底。我们的研究小组建议进行甲状腺切除术和功能性颈清扫术，随后进行放化疗。对患者进行密切的多学科随访是必要的。我们外科在1949年至1982年间治疗了1048例甲状腺恶性肿瘤。26例患者（2.4%）被诊断为甲状腺髓样癌。随访时间为1个月至17年。无复发生存期为4.5年。5年和10年生存率分别为52%和26%。
